Clinical Trial Update: Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the safety, tolerability, pharmacodynamics and efficacy of CNP-106 in subjects with Myasthenia gravis is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• CNP-106

Snippet

Sponsor: COUR Pharmaceutical Development Company, Inc. | Conditions: Myasthenia Gravis, Generalized Myasthenia | Phase 1, Phase 2 | Status: RECRUITING